

## **ASX Announcement**

### **Appendix 3Y – Dr John Cullity**

**3 September 2021** – Race Oncology Limited (“Race”) advises that Dr John Cullity, through the holding company Biosynergy Partners Pty Ltd, has sold 61,745 shares for the purposes of covering the costs associated with the exercise of 1,893,939 options as announced on 23 August 2021.

A copy of the Appendix 3Y for Dr Cullity is attached.

-ENDS

#### **About Race Oncology (ASX: RAC)**

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene® (bisantrene dihydrochloride).

Zantrene® is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene® as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development and regulatory approval of Zantrene®.

See more at [www.raceoncology.com](http://www.raceoncology.com).

#### **Release authorised by:**

Phil Lynch, CEO/MD on behalf  
of the Race Board of Directors  
[phillip.lynch@raceoncology.com](mailto:phillip.lynch@raceoncology.com)

#### **Media contact:**

Jane Lowe  
+61 411 117 774  
[jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Race Oncology Limited</b>
<b>ABN</b>	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>Dr John Cullity</b>
<b>Date of last notice</b>	<b>23 August 2021</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	1. Craganorig Holdings, LLC – director related entity 2. Biosynergy Partners Pty Ltd – director related entity
<b>Date of change</b>	31 August 2021, 1 and 2 September 2021
<b>No. of securities held prior to change</b>	1. 2,000,000 Options exercisable at \$0.23, expiring 27/11/2021, subject to vesting conditions. 2. 5,681,817 Ordinary Shares 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 189,394 Options exercisable at \$4.50, expiring 16/5/2022
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	Nil
<b>Number disposed</b>	2. 61,745 Ordinary shares
<b>Value/Consideration includes brokerage/gst</b> Note: If consideration is non-cash, provide details and estimated valuation	\$192,798.78

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>2,000,000 Options exercisable at \$0.23, expiring 27/11/2021, subject to vesting conditions.</li> <li>5,620,072 Ordinary Shares 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 189,394 Options exercisable at \$4.50, expiring 16/5/2022</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market sale of shares to cover the costs of exercise of options.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.